stockrowOrganigram Global Inc.
OGI Healthcare Drug Manufacturers Specialty & Generic
Organigram Global Inc.’s revenue for fiscal 2025 (year ended September 2025) was $185.3 million, up 57.7% from fiscal 2024.
- Revenue
- +49.3%
- EPS
- +1,966.7%
- Free cash flow
- −192.3%
Quarter to June 2026, against a year earlier
Follow OGI
Alert me
Organigram Global Inc. (OGI) P/E ratio
As of 5 November 2026, Organigram Global Inc. (OGI) trades at a P/E ratio of 2.0×. Over the past ten years it has ranged from 0.0× (June 2026) to 266× (October 2016); the current reading is higher than 83% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 20.5× and below the Healthcare sector median of 25.2×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 30.0× | 0.00% |
| FY2017 | 30.0× | 0.00% |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 2.2× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 12.0× | — |
| Sep 2025 | 0.0× | — |
| 28 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SIGA Siga Technologies Inc. compare | n/m |
| ADCT ADC Therapeutics SA compare | n/m |
| DERM Journey Medical Corporation compare | n/m |
| GLAS Glass House Brands Inc. compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| ORGO Organogenesis compare | n/m |
| CRDL Cardiol Therapeutics Inc. compare | n/m |
| OGI Organigram Global Inc. | 2.0× |
| BGM BGM Group Ltd. compare | 148× |
| Drug Manufacturers Specialty & Generic industry median | 20.5× |
| Healthcare sector median | 25.2× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)